Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

Similar articles for PubMed (Select 7530585)

1.

Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.

Cheeseman SH, Havlir D, McLaughlin MM, Greenough TC, Sullivan JL, Hall D, Hattox SE, Spector SA, Stein DS, Myers M, et al.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Feb 1;8(2):141-51.

PMID:
7530585
2.
3.

Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity.

de Jong MD, Loewenthal M, Boucher CA, van der Ende I, Hall D, Schipper P, Imrie A, Weigel HM, Kauffmann RH, Koster R, et al.

J Infect Dis. 1994 Jun;169(6):1346-50.

PMID:
8195615
4.

Zidovudine and lamivudine: results of phase III studies.

Staszewski S.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S57.

PMID:
8595510
5.
6.

Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.

Meng TC, Fischl MA, Boota AM, Spector SA, Bennett D, Bassiakos Y, Lai SH, Wright B, Richman DD.

Ann Intern Med. 1992 Jan 1;116(1):13-20.

PMID:
1345755
7.

Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.

Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K, Pauletti D, et al.

J Virol. 1994 Mar;68(3):1660-6.

8.

The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.

Fischl MA, Resnick L, Coombs R, Kremer AB, Pottage JC Jr, Fass RJ, Fife KH, Powderly WG, Collier AC, Aspinall RL, et al.

J Acquir Immune Defic Syndr. 1994 Feb;7(2):139-47.

PMID:
7905523
9.

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection.

Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, Greenough TC, Sullivan JL, Hall D, Myers M, et al.

J Infect Dis. 1995 Mar;171(3):537-45.

PMID:
7533197
11.

Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.

Bartlett JA, Benoit SL, Johnson VA, Quinn JB, Sepulveda GE, Ehmann WC, Tsoukas C, Fallon MA, Self PL, Rubin M.

Ann Intern Med. 1996 Aug 1;125(3):161-72.

PMID:
8686973
12.

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, Merigan TC.

Ann Intern Med. 1996 Jun 15;124(12):1039-50.

PMID:
8633817
13.

Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children.

Luzuriaga K, Bryson Y, McSherry G, Robinson J, Stechenberg B, Scott G, Lamson M, Cort S, Sullivan JL.

J Infect Dis. 1996 Oct;174(4):713-21.

14.
16.

Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team.

Reichman RC, Morse GD, Demeter LM, Resnick L, Bassiakos Y, Fischl M, Para M, Powderly W, Leedom J, Greisberger C, et al.

J Infect Dis. 1995 Feb;171(2):297-304.

PMID:
7531207
17.
18.
19.

Nevirapine approved by FDA. Food and Drug Administration.

Bowersox J.

NIAID AIDS Agenda. 1996 Sep:10.

PMID:
11363918
20.

Nevirapine triple combo results released.

[No authors listed]

Common Factor. 1995 Apr;(no 10):21.

PMID:
11362346
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk